Tenderwize
Back to tender search

Medicinal product with olodaterol and tiotropium bromide (ATC: R03AL06)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Apr 29, 2027 · 251 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Olodaterol und Tiotropiumbromid (ATC: R03AL06)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No estimated contract value or budget is disclosed, so potential revenue cannot be assessed.

If the authority awards exclusive contracts during the term, the open-house contracts will be terminated.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for finished medicinal products containing olodaterol and tiotropium bromide (ATC: R03AL06)
  • Open-house model: any qualified pharmaceutical company can join at any time
Show full summary

This is an open-house model for non-exclusive discount agreements under § 130a Abs. 8 SGB V for finished medicinal products containing the active substances olodaterol and tiotropium bromide (ATC: R03AL06). The contracting authority is AOK Sachsen-Anhalt. Any qualified pharmaceutical company can join at any time under standard terms. The contract runs from 1 July 2025 to 30 June 2027 (max 24 months). There is no estimated value provided. The procedure is not a public procurement under EU law despite using an open procedure notice form. Submission is via postal mail or electronically with qualified electronic signature. The deadline for submission is 30 April 2027, but the model allows participation at any time until that date.

Risks

No estimated contract value or budget is disclosed, so potential revenue cannot be assessed.

If the authority awards exclusive contracts during the term, the open-house contracts will be terminated.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company or a group of pharmaceutical companies

Administrative

  • Complete and sign the participation documents
  • Submit participation documents via postal mail or electronically with qualified electronic signature

Award Criteria

Lot 1

No award criteria defined; open to all qualifying companies.

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Medicinal product with olodaterol and tiotropium bromide (ATC: R03AL06)

Non-exclusive discount agreements for finished medicinal products containing olodaterol and tiotropium bromide (ATC: R03AL06) under an open-house model. Any eligible pharmaceutical company can conclude a contract at any time. Contract duration maximum 24 months ending 30 June 2027. The contract may be terminated if the authority awards exclusive contracts later.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Award Criteria

No award criteria defined; open to all qualifying companies.

Deadline

Deadline Apr 29, 2027

Procurement Details

Publication date
18 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
320165-2025

Documents (1)

Similar tenders